S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:BMRA

Biomerica (BMRA) Stock Price, News & Analysis

$0.89
0.00 (0.00%)
(As of 03/27/2024 ET)
Today's Range
$0.85
$0.90
50-Day Range
$0.85
$1.29
52-Week Range
$0.70
$2.13
Volume
62,636 shs
Average Volume
86,240 shs
Market Capitalization
$14.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
BMRA stock logo

About Biomerica Stock (NASDAQ:BMRA)

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

BMRA Stock Price History

BMRA Stock News Headlines

Biomerica Inc BMRA
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
Biomerica Inc.
BMRA Mar 2024 2.500 call
Trending Stocks Sent To You In Real Time
Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar!
Biomerica Reports Second Quarter 2024 Financial Results
Nasdaq Gains 100 Points; Biomerica Shares Spike Higher
REPEAT - Biomerica Reports First Quarter 2024 Financial Results
Biomerica Reports First Quarter 2024 Financial Results
See More Headlines
Receive BMRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomerica and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
1/16/2024
Today
3/27/2024
Next Earnings (Estimated)
4/12/2024
Fiscal Year End
5/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
N/A
Current Symbol
NASDAQ:BMRA
Employees
62
Year Founded
1971

Profitability

Net Income
$-7,140,000.00
Net Margins
-110.58%
Pretax Margin
-109.15%

Debt

Sales & Book Value

Annual Sales
$5.34 million
Book Value
$0.70 per share

Miscellaneous

Free Float
14,551,000
Market Cap
$14.97 million
Optionable
Optionable
Beta
-1.01

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Zackary S. Irani (Age 58)
    Chief Executive Officer
    Comp: $141.25k
  • Mr. Allen C. Barbieri (Age 66)
    Executive Vice-Chairman of the Board & Corporate Secretary
    Comp: $126.25k
  • Mr. Gary Lu CPA (Age 43)
    Principal Accounting Officer & CFO
    Comp: $260k
  • Ms. Lucy Liu Ph.D.
    Director of Manufacturing & Technical Operations
  • Mr. Robert W. Carlson
    Chief Commercial Officer

BMRA Stock Analysis - Frequently Asked Questions

How have BMRA shares performed in 2024?

Biomerica's stock was trading at $1.25 at the beginning of 2024. Since then, BMRA stock has decreased by 28.8% and is now trading at $0.89.
View the best growth stocks for 2024 here
.

Are investors shorting Biomerica?

Biomerica saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 76,700 shares, a decrease of 42.5% from the February 29th total of 133,500 shares. Based on an average daily volume of 102,500 shares, the short-interest ratio is currently 0.7 days.
View Biomerica's Short Interest
.

When is Biomerica's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, April 12th 2024.
View our BMRA earnings forecast
.

How were Biomerica's earnings last quarter?

Biomerica, Inc. (NASDAQ:BMRA) released its quarterly earnings results on Tuesday, January, 16th. The company reported ($0.09) earnings per share (EPS) for the quarter. The company had revenue of $1.57 million for the quarter. Biomerica had a negative trailing twelve-month return on equity of 64.25% and a negative net margin of 110.58%.

What other stocks do shareholders of Biomerica own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biomerica investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Johnson & Johnson (JNJ), OPKO Health (OPK), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), Co-Diagnostics (CODX), FuelCell Energy (FCEL) and Trevena (TRVN).

Who are Biomerica's major shareholders?

Biomerica's stock is owned by many different institutional and retail investors. Top institutional shareholders include Granahan Investment Management LLC (6.44%), Vanguard Group Inc. (3.62%), Vanguard Group Inc. (3.62%), Russell Investments Group Ltd. (1.20%), Heritage Investors Management Corp (0.21%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Allen Barbieri, Catherine Coste and Zackary S Irani.
View institutional ownership trends
.

How do I buy shares of Biomerica?

Shares of BMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BMRA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners